Stay Up-to-Date With the Latest Industry News
Discover the latest news within the Novel Conjugate field, and which sessions on our agenda will allow you to explore these topics further.
Fortitude launches with $13M in financing - harnessing the power of its GLUE-DACTM drug discovery engine to advance therapeutics for oncology and autoimmune diseases
Speakers Include: EMD Serono & Baylink Biosciences
Eli Lilly & InduPro partner on $950M initiative to develop bispecific ADCs and tri-specific antibodies
Speakers Include: Valink Therapeutics, BiVictriX Therapeutics & TwoStep Therapeutics
Cancer Breakthrough: Daiichi Sankyo launches inaugural STING agonist ADC
Speakers Include: Pfizer, Sutro Biopharma & Bolt Biotherapeutics
Explore the Full Event Guide
- 20+ companies showcasing the rationale and data behind their approach in novel conjugate development
- 5+ pharma search & evaluation experts discussing partnerships within novel conjugates
- 6+ networking hours for learning from others in the space and forming brand new connections
- 2 deep dive workshops for cross-modality collaboration and optimising the design of novel conjugate drugs
- A poster session for allowing delegates to showcase cutting-edge work to the audience
Explore the Agenda
Discover the latest differentiated approaches in bioconjugate design, from next-generation payloads to novel targeting formats. Gain deep insights through data-rich case studies, interactive workshops, and strategic panel discussions.
Partner With Us
Showcase your capabilities alongside leading CDMOs, technology providers, and biopharma innovators shaping the future of ADCs and next-generation conjugates. Position your brand at the center of industry-defining partnerships.
Join Conjugate Experts
Connect with the scientists, business developers, and external innovation leaders driving the evolution of targeted drug conjugates, and build the collaborations that will shape tomorrow’s precision therapeutics.